Premium
Feasibility of daily concurrent chemoradiation therapy as nonsurgical management for esophageal cancer: Our experience and theoretical background
Author(s) -
Shimoyama Shouji,
Aoki Fumio,
Murakami Toshikazu,
Toyoda Kenji,
Kaminishi Michio
Publication year - 2000
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/1096-9098(200006)74:2<134::aid-jso10>3.0.co;2-2
Subject(s) - medicine , esophageal cancer , radiation therapy , chemoradiotherapy , general surgery , surgery , cancer , oncology
Background and Objectives Many combination patterns of chemotherapy and radiotherapy (chemoradiation therapy; CRT) for the treatment of esophageal cancer indicate that the optimal doses of chemotherapeutic agents and of chemotherapy and radiotherapy regimens remain unclear. The feasibility and promising outcome of our newly developed definitive CRT for nonsurgical management of esophageal cancer, essentially based on the theoretical backgrounds of the radiosensitizing and biochemical modulation effects of chemotherapeutic agents, is investigated. Methods Six nonoperated esophageal cancer patients were treated by daily concurrent CRT, which consisted of continuous 5‐fluorouracil administration with leucovorin, combined with a low dose of daily cisplatin administration before each fraction of radiation. Response to CRT and toxicities and survivals were evaluated. Results Complete and partial responses were seen in 2 patients each. Histologic examination of the biopsy specimens in the primary site showed no cancer cells in 4 patients; 1 of them survived for 31 months after CRT. The other 2 patients showed good‐quality survival, having dramatic relief from dysphagia. There were no treatment‐related deaths Conclusions The daily concurrent CRT is rational and promising and compares well with other series of definitive CRT. The CRT based on the theoretical background is feasible as a nonsurgical management option for esophageal cancer patients. J. Surg. Oncol. 2000;74:134–137. © 2000 Wiley‐Liss, Inc.